Revisited the potential risks of carcinogenicity of phototherapy in patients with psoriasis

Cover Page

Abstract


The article presents published data on the assessment of the risk of cancerogenicity of multiple courses of phototherapy methods such as PUVA therapy and UVB-311 in psoriatic patients. The authors analyzed the incidence of malignant skin neoplasms (squamous cell carcinoma, basal cell carcinoma, malignant skin melanoma) among psoriatic patients from different population groups taking into account the cumulative radiation doses and number of procedures.

A. A. Kubanov

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: noemail@neicon.ru

Russian Federation

M. B. Zhilova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: zhilova@cnikvi.ru

Russian Federation

  1. Tessman J.W., Isaacs S.T., Hearst J.E. Photochemistry of the furan-side 8-methoxypsoralen-thymidine monoadduct inside the DNA helix. Conversion to diadduct and to pyroneside monoadduct. Biochemistry 1985; 24: 1669-1676.
  2. Neuner P., Charvat B., Knobler R., Kirnbauer R., Schwarz A., Luger T.A., Schwarz T. Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UV-A. Photochem Photobiol 1994; 59: 182-188.
  3. Johnson R., Staiano-Coico L., Austin L., Cardinale I., Nabeya-Tsukifuji R., Krueger J.G. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63: 566-571.
  4. Weichenthal M., Schwarz T. Phototherapy: how does UV work? Photodermatol Photoimmunol Photomed 2005; 21: 260-266.
  5. Schwarz T., Luger T.A. Effect of UV irradiation on epidermal cell cytokine production. J Photochem Photobiol B Biol 1989; 4: 1-13.
  6. Kripke M.L., Cox P.A., Alas L.G., Yarosh D.B. Pyrimidine dimers in DNA initiate systemic immunosuppression in UVB-irradiated mice. Proc Natl Acad Sci USA 1992; 89: 7516-7520.
  7. Lebwohl M., Martinez J., Weber P., De Luca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 1995; 32: 469-471.
  8. Ibbotson S.H., Farr P.M. The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 1999; 113: 346-350.
  9. Shahtmejster I.Ja., Pisarenko M.F., Vladimirov V.V. i dr. Otdalennye rezul'taty PUVA-terapii u bol'nyh psoriazom. Vestnik dermatologii i venerologii 1982; 12: 7-9. [Шахтмейстер И.Я., Писаренко М.Ф., Владимиров В.В. и др. Отдаленные результаты ПУВА-терапии у больных псориазом. Вестник дерматологии и венерологии 1982; 12: 7-9].
  10. Akovbjan V.A. Obosnovanie ogranichitel'nogo rezhima FHT psoriaza v uslovijah jekologicheskoj insoljacii. Vestnik dermatologii i venerologii 1987, 7: 40-42. [Аковбян В.А. Обоснование ограничительного режима ФХТ псориаза в условиях экологической инсоляции. Вестник дерматологии и венерологии 1987; 7: 40-42].
  11. Zavadskij V.N., EseninA.A. Mnozhestvennyj ploskokletochnyj rak kozhi u bol'nogo psoriaticheskoj jeriterodermiej. Vestnik dermatologii i venerologii 1982; 2: 65. [Завадский В.Н., Есенин А.А. Множественный плоскоклеточный рак кожи у больного псориатической эритеродермией. Вестник дерматологии и венерологии 1982; 2: 65].
  12. Marzeeva G.I., Trofimova L.Ja., Kirsanova M.M. Jeffektivnost' fotohimioterapii pri psoriaticheskoj jeritrodermii. Vestnik dermatologii i venerologii 1982; 6: 8-12. [Марзеева Г.И., Трофимова Л.Я., Кирсанова М.М. Эффективность фотохимиотерапии при псориатической эритродермии. Вестник дерматологии и венерологии 1982; 6: 8-12].
  13. Hapilova V.I., Trofimova L.Ja., Bol'shakova G.M. Materialy k otdalennym rezul'tatam lechenija bol'nyh psoriazom. Vestnik dermatologii i venerologii1990; 5: 12-13. [Хапилова В.И., Трофимова Л.Я., Большакова Г.М. Материалы к отдаленным результатам лечения больных псориазом. Вестник дерматологии и венерологии 1990; 5: 12-13].
  14. Molochkov V.A., Kuncevich Zh.S. Sluchaj razvitija gigantskoj keratoakantomy posle PUVA-terapii. Klinicheskaja dermatologija i venerologija 2003; 4: 20-21. [Молочков В.А., Кунцевич Ж.С. Случай развития гигантской кератоакантомы после ПУВА-терапии. Клиническая дерматология и венерология 2003; 4: 20-21].
  15. Stern R.S., Laird N., Melski J., Parrish J.A., Fitzpatrick T.B., Bleich H.L. Cutaneous squamouscell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156-1161.
  16. Stern R.S., Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-124.
  17. Stern R.S. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med 1990; 322: 1093-1097.
  18. Stern R.S., Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Archives Of Dermatology 1998 Dec; Vol. 134 (12), pp. 1582-5.
  19. Stern R.S., Liebman E.J., Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of non-melanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-1284.
  20. Stern R.S. PUVA Follow-Up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761.
  21. Stern R.S., Bagheri S., Nichols K. et al. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002; 47: 33-39.
  22. Nijsten T.E., Stern R.S. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644-650.
  23. Katz K.A., Marcil I., Stern R.S. et al. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen+ ultraviolet a light-treated psoriasis patients. J Invest Dermatol 2002; 118: 1038-1043.
  24. Honigsmann H., Wolff K., Gschnait F. et al. Keratoses and nonmelanoma skin tumors in longterm photochemotherapy (PUVA). J Am Acad Dermatol 1980; 3: 406-414.
  25. Henseler T., Christophers E. Risk of skin tumors in psoralen- and ultraviolet A-treated patients. Natl Cancer Inst Monogr 1984; 66: 217-219.
  26. Henseler T., Christopher E., Honigsmann H. et al. Skin tumors in the European PUVA study. J Am Acad Dermatol 1987; 16: 108-111.
  27. Cox N.H., Jones S.K., Downey D.J. et al. Cutaneous and ocular side-effectsof oral photochemotherapy: results of an 8-year follow-up study. Br J Dermatol 1987; 116: 145-152.
  28. Bruynzeel I., Bergman W., Hartevelt H.M. et al. "High single-dose" European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55.
  29. Lindeloèf B., Sigurgeirsson B., Tegner E., Larkoè O., Johannesson A., Berne B., Ljunggren B., Andersson T., Molin L., Nylanderlundqvist E., Emtestam L. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-112.
  30. Hannuksela-Svahn A., Pukkala E., Koulu L., Jansen C.T., Karvonen J. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol 1999; 1: 694-696.
  31. BruynzeelI I., Bergman W., Hartevelt H.M. et al. ‘High single-dose’ European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55.
  32. Lassus A., Reunala T., Idänpää-Heikkilä J et al. PUVA treatment andskin cancer: a follow-up study. Acta Derm Venereol (Stockh) 1981; 61: 141.
  33. Lindskov R. Skin carcinomas and treatment with photochemotherapy. Acta Derm Venereol (Stockh) 1983; 63: 223-226.
  34. Ros A.M., Wennersten G., Lagerholm B. et al. Long-term photochemotherapy for psoriasis: a histopathological and clinical follow-up study with special emphasis on tumour incidence and behavior of pigmented lesions. Acta Derm Venereol (Stockh) 1983; 63: 215-221.
  35. Reshad H., Challoner F., Pollock D.J. et al. Cutaneous carcinoma in psoriatic patients treated with PUVA. Br J Dermatol 1984; 110: 299-305.
  36. Eskelinen A., Halme K., Lassus A. et al. Risk of cutaneous carcinoma in psoriatic patients treated with PUVA. Photodermatol 1985; 2: 10-14.
  37. Torinuki W., Tagami H. Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy, Goeckerman regimen, or both therapies. A 10-year follow up study. J Am Acad Dermatol 1988; 18: 1278-1281.
  38. Tanew A., Honigsmann H., Ortel B. et al. Nonmelanoma skin tumors in long-term photochemotherapy treatment of psoriasis. An 8-year followup study. J Am Acad Dermatol 1986; 15: 960-965.
  39. Abdullah A.N., Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy - a 10-year follow-up study. Clin Exp Dermatol 1989; 14: 421-424.
  40. BruynzeelI I., Bergman W., Hartevelt H.M. et al. ‘High single-dose’ European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55. 145.
  41. Lindelof B., Sigurgeirsson B., Tegner E. et al. Comparison of the carcinogenic potential of tri-oxsalen bath PUVA and oral methoxsalen PUVA. Arch Dermatol 1992; 128: 1341-1344.
  42. Lever L.R., Farr P.M. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131: 215-219.
  43. Mc Kenna K.E., Patterson C.C., Handley J. et al. Cutaneous neoplasia following PUVA therapy for psoriasis. Br J Dermatol 1996; 134: 639-642.
  44. Gritiyarangsan P., Sindhavananda J., Rungrairatanaroj P. et al. Cutaneous carcinoma and PUVA lentigines in Thai patients treated with oral PUVA. Photodermatol Photoimmunol Photomed 1995; 11: 174-177.
  45. Maier H., Schemper M., Ortel B. et al. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology 1996; 193: 185-191.
  46. Chuang T.Y., Heinrich L.A., Schultz M.D. et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26: 173-177.
  47. Stern R.S. PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012 Apr; 66 (4): 553-62.
  48. Gupta A.K., Stern R.S., Swanson N.A., Anderson T.F. Cutaneous melanomas in patients treated with psoralens plus ultraviolet A. A case report and the experience of the PUVA follow-up study. J Am Acad Dermatol 1988; 19: 67-76.
  49. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 1997; 336: 1041-1045.
  50. Chen Y.J., Wu C.Y., Chen T.J. et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 2011; 65: 84-91.
  51. Hannuksela-Svahn A., Pukkala E., Laara E. et al. Psoriasis, its treatment, and cancer in a cohort of Finnish Patients. J Invest Dermatol 2000; 114: 587-590.
  52. Frentz G., Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol. 1999 Feb; 140 (2): 237-42.
  53. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E. et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999; 141: 497-501.
  54. Ji J., Shu X., Sundquist K., Sundquist J., Hemminki K. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer. 2009 May 5; 100 (9): 1499-502.
  55. Patel R.V., Clark L.N., Lebwohl M., Weinberg J.M. Treatments for psoriasis and the risk of malignancy. // J. Am. Acad. Dermatol. 2009 Jun; 60 (6): 1001-17.
  56. Whiteman D.C., Parsons P.G., Green А. P53 Expression and risk factors for cutaneous melanoma: A case-control study. Int. J. Cancer 1998; 77, 843-848.
  57. Pasker-de Jong P.C., Wielink G., Valk P.G., Wilt G.J. Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Arch Dermatol. 1999 Jul; 135 (7): 834-40.
  58. Lee E., Koo J., Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005 May; 44 (5): 355-60.
  59. Osmancevic A., Gillstedt M., Wennberg A.M., Larkö O. The Risk of Skin Cancer in Psoriasis Patients Treated with UVB Therapy. Acta Derm Venereol. 2014 Jul; 94 (4): 425-30.
  60. Weischer M., Blum A., Eberhard F., Rocken M., Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84: 370-374.
  61. Man I., Crombie I.K., Dawe R.S. et al. The pho-tocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 2005; 152: 755-757.
  62. Black R.J., Gavin A.T. Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data. Br J Dermatol 2006; 154: 566-567.
  63. Hearn R.M., Kerr A.C., Rahim K.F., Ferguson J., Dawe R.S. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008 Sep; 159 (4): 931-5.
  64. Lim J.L., Stern R.S. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 2005; 124: 505-513.
  65. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114-135.
  66. Weischer M., Blum A., Eberhard F. et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm. Venereol 2004; 84: 370-374.
  67. Ibbotson S.H., Bilsland D., Cox N.H., Dawe R.S., Diffey B., Edwards C. et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151: 283-297.
  68. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation.Nature 2008, 454: 436-444.
  69. Grivennikov S.I., Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010, 20: 65-71.
  70. Schmidlin K., Spoerri A., Egger M., Zwahlen M., Stuck A., Clough-Gorr K. Cancer, a disease of aging - part 1. Swiss Med Wkly 2012; 142: 0.
  71. Schmidlin K., Spoerri A., Egger M., Zwahlen M., Stuck A., Clough-Gorr K. Cancer, a disease of aging - part 2. Swiss Med Wkly 2012; 142: 0.
  72. Green A., Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990; 46: 356-361.
  73. Nestor M.S., Zarraga M.B. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. J Clin Aesthet Dermatol 2012; 5: 20-24.
  74. Weinstock M.A. The epidemic of squamous cell carcinoma. JAMA 1989; 262: 2138-2140.
  75. Leonardi-Bee J., Ellison T., Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: Systematic review and Meta-analysis. Arch Dermatol 2012; 148: 939-946.
  76. El-Gabalawy H., Guenther L.C., Bernstein C.N. Epidemiology of immunemediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 2010, 85 (Imid): 2-10.
  77. Margolis D., Bilker W., Hennessy S., Vittorio C., Santanna J., Strom B.L: The risk of malignancy associated with psoriasis. Arch Dermatol 2001, 137: 778-783.
  78. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759-2764.
  79. Pouplard C., Brenaut E., Horreau C., Barnetche T., Misery L., Richard M., Aractingi S., Aubin F., Cribier B., Joly P., Jullien D., Le-Maître M., Ortonne J.-P., Paul C. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013, 27 (Suppl 3): 36-46.
  80. Richard M., Barnetche T., Horreau C., Brenaut E., Pouplard C., Aractingi S., Aubin F., Cribier B., Joly P., Jullien D., Le-Maître M., Misery L., Ortonne J.-P., Paul C. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidencebased recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013, 27 (Suppl 3): 2-11.

Views

Abstract - 63

PDF (Russian) - 36

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies